Detalhe da pesquisa
1.
American Cancer Society prostate cancer survivorship care guidelines.
CA Cancer J Clin
; 64(4): 225-49, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24916760
2.
Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
Prostate
; 76(5): 512-20, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26689606
3.
Kidney Cancer: Toxicity Management, Symptom Control, and Palliative Care.
J Clin Oncol
; : JCO2018790188, 2018 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30372391
4.
Phase I trial with a combination of docetaxel and ¹5³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
Urol Oncol
; 29(6): 670-5, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-19962920
5.
Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.
Clin Interv Aging
; 2(4): 555-60, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-18225455
6.
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Cancer Biol Ther
; 6(9): 1360-7, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17786033
7.
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
Am J Clin Oncol
; 29(4): 395-8, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16891869
8.
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Cancer
; 94(5): 1457-65, 2002 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11920502